Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2015

View Archived Issues

Trevi Therapeutics reports data from phase II/III trial in uremic pruritus

Roche patents mGluR4 PAMs

Gencia and Takeda to discover and develop mitochondrial therapeutic compounds

Isis Pharmaceuticals and AstraZeneca collaboration receives antitrust clearance

Theravance Biopharma and Mylan begin phase III program for revefenacin in COPD

Sanofi reports topline results from phase III LixiLan-L trial

CAT-1004 receives rare pediatric disease designation for Duchenne muscular dystrophy

FDA awards orphan drug designation to MANF for retinal artery occlusion

DNDi and Eisai partner to develop fosravuconazole for eumycetoma

Elevated N-acetylspermidine, a potential biomarker for Snyder Robinson syndrome

Imbruvica NDA submitted to FDA for treatment-naive chronic lymphocytic leukemia

Cancer Research Technology discloses Mps1 inhibitors

World Lymphoma Awareness Day: Chemotherapy-free regimens make progress

Indian CSIR presents PI3Kalpha inhibitors

Riboflavin metabolism abnormalities may induce MADD

Laguna opens phase III RESTORE SR trial of vanoxerine for atrial fibrillation and atrial flutter

FDA accepts IND application for AEB-1102

Achillion discovers complement factor D inhibitors

FORUM and Mitsubishi Tanabe Pharma halt encenicline trials following FDA clinical hold

LIPT2 gene mutations may be associated with lipoic acid biosynthesis defects

Abeta deposition found in subjects with prion disease transmitted by medical treatment

NantPharma licenses Amgen's c-Met inhibitor AMG-337

Erytech seeks EMA approval for Graspa in ALL

Zenyaku Kogyo terminates blisibimod Japanese license agreement with Anthera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...